论文部分内容阅读
目的探讨结直肠癌组织GOLPH2的表达与临床病理参数和预后的关系。方法随机选取145例确诊的结直肠癌患者的癌组织,另选取30例结直肠癌患者的癌旁组织,采用免疫组化法检测GOLPH2的表达,分析其表达程度与临床病理参数和预后的关系。结果 GOLPH2在结直肠癌组织中的阳性表达率为81.38%,明显高于癌旁组织,差异有统计学意义(P=0.001)。在中低分化组织、临床分期3期~4期组织和淋巴结转移中GOLPH2均为高表达,其高表达率明显高于高分化、1期~2期及无淋巴结转移组织,差异有统计学意义(P=0.001)。随访5年,GOLPH2阳性表达组术后1年的累积生存率为41.82%,明显低于GOLPH2阴性表达组,差异有统计学意义(P=0.001),但与术后3年和5年生存率、复发率和转移率差异无统计学意义(P>0.05)。结论 GOLPH2在结直肠癌组织中存在高表达,其表达程度与肿瘤分化程度、临床分期及术后短期生存率密切相关,可能是结直肠癌发生、发展的重要机制之一。
Objective To investigate the relationship between the expression of GOLPH2 and clinicopathological parameters and prognosis in colorectal cancer. Methods A total of 145 cancerous tissues from patients with colorectal cancer were selected randomly. The adjacent tissues of 30 colorectal cancer patients were selected. The expression of GOLPH2 was detected by immunohistochemistry. The relationship between the expression of GOLPH2 and clinicopathological parameters and prognosis . Results The positive expression rate of GOLPH2 in colorectal cancer tissues was 81.38%, which was significantly higher than that in paracancerous tissues (P = 0.001). In moderately and poorly differentiated tissues, GOLPH2 was highly expressed in stage 3 to stage 4 and lymph node metastasis, and the high expression rate was significantly higher than that in well differentiated, stage 1 to stage 2 and no lymph node metastasis, the difference was statistically significant (P = 0.001). After 5 years of follow-up, the cumulative survival rate at 1 year after GOLPH2 positive expression was 41.82%, which was significantly lower than that in GOLPH2 negative group (P = 0.001), but not significantly different from 3 and 5 year survival rates There was no significant difference in recurrence rate and metastasis rate (P> 0.05). Conclusion The expression of GOLPH2 is highly expressed in colorectal cancer tissues. The expression of GOLPH2 is closely related to the degree of tumor differentiation, clinical stage and short-term survival rate, which may be one of the important mechanisms for the occurrence and development of colorectal cancer.